Clinical Trials Logo
  1. Home
  2. Eosinophilic Asthma
  3. NCT01270464

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma Clinical Trial

Official title:
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Clinical Trial Summary

The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01270464
Study type Interventional
Source Teva Pharmaceutical Industries
Contact
Status Completed
Phase Phase 3
Start date December 2010
Completion date December 2013
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05398133 - Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
Recruiting NCT04585997 - Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab". Phase 4
Recruiting NCT05985694 - AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma Phase 2
Completed NCT03563521 - Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
Completed NCT03469934 - Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma Phase 2
Recruiting NCT04187976 - Eosinophils Endotypes in Chronic Airway Inflammatory Diseases
Recruiting NCT05813288 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Phase 3
Completed NCT01285323 - A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Phase 3
Completed NCT03696914 - Intense Airway Eosinophilia in Asthma
Terminated NCT01290887 - Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Phase 3
Recruiting NCT04228588 - A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil Phase 4
Recruiting NCT05748600 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Phase 3
Recruiting NCT05763121 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Phase 3
Completed NCT01508936 - Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Phase 3
Recruiting NCT04538937 - Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
Completed NCT05002621 - Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
Completed NCT04674137 - XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma Phase 2
Recruiting NCT04671446 - Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Completed NCT04046939 - Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma Phase 2
Completed NCT01287039 - A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Phase 3